AnaptysBio, Inc. (AN6.F)

24.00 +0.40 (+1.69%) At close: 09:55PM CEST

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
United States
858 362 6295
https://www.anaptysbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 117

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Daniel R. Faga	President, CEO & Director	2.34M	N/A	1980
Mr. Eric J. Loumeau	Chief Legal Officer	670.57k	N/A	1963
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.	Chief Medical Officer	686.24k	N/A	1975
Mr. Dennis M. Mulroy	Chief Financial Officer	416.84k	N/A	1955
Ms. Beth Mueller	Senior Vice President of Human Resources	N/A	N/A	N/A
Dr. Martin Dahl Ph.D.	Senior Vice President of Research	N/A	N/A	N/A
Mr. Benjamin Stone	Chief Business Officer	N/A	N/A	N/A
Mr. Douglas A. Rich M.B.A.	Senior Vice President of CMC	N/A	N/A	1969
Ms. Monique Da Silva	Senior Vice President of Corporate Affairs	N/A	N/A	N/A
Ms. Priya Raina	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Corporate Governance

AnaptysBio, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.